Literature DB >> 31396854

Overexpression of Histone H3 Lysine 27 Trimethylation Is Associated with Aggressiveness and Dedifferentiation of Thyroid Cancer.

Chia-Chi Tsai1, Ming-Nan Chien2, Yuan-Ching Chang1, Jie-Jen Lee1, Shuen-Han Dai3, Shih-Ping Cheng4,5.   

Abstract

A variety of epigenetic dysregulations are observed in thyroid malignancies. EZH2, the catalytic subunit of polycomb repressive complex 2, is upregulated in advanced thyroid cancers. EZH2 can catalyze trimethylation of histone H3 at lysine 27 (H3K27me3) and contribute to transcriptional silencing of target genes. Here, we investigated the immunohistochemical expression of H3K27me3 in neoplastic and normal thyroid tissues. Normal thyroid epithelial cells typically exhibited nuclear staining of moderate intensity. A similar expression pattern was observed in nodular goiters and follicular adenomas. By contrast, strong H3K27me3 expression was evident in 80% (8/10) lymphocytic thyroiditis, 63% (80/127) papillary thyroid cancer, 41% (7/17) follicular thyroid cancer, and 73% (8/11) poorly differentiated and anaplastic thyroid cancer. In differentiated thyroid cancer, strong H3K27me3 expression was associated with extrathyroidal extension (p < 0.001), lymphovascular invasion (p = 0.029), lymph node metastasis (p = 0.006), and higher risk of recurrence (p = 0.003). Our results indicate that H3K27me3 overexpression may be implicated in aggressiveness and dedifferentiation of thyroid cancer. In addition to prognostication, the predictive value of H3K27me3 expression deserves further investigation given the recent development of epigenetic targeting agents.

Entities:  

Keywords:  EZH2; H3K27me3; Immunohistochemistry; Thyroid cancer

Mesh:

Substances:

Year:  2019        PMID: 31396854     DOI: 10.1007/s12022-019-09586-1

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  31 in total

Review 1.  The epigenetic landscape of differentiated thyroid cancer.

Authors:  Sylvia L Asa; Shereen Ezzat
Journal:  Mol Cell Endocrinol       Date:  2017-07-12       Impact factor: 4.102

2.  Overexpression of teneurin transmembrane protein 1 is a potential marker of disease progression in papillary thyroid carcinoma.

Authors:  Shih-Ping Cheng; Ming-Jen Chen; Ming-Nan Chien; Chi-Hsin Lin; Jie-Jen Lee; Chien-Liang Liu
Journal:  Clin Exp Med       Date:  2016-12-21       Impact factor: 3.984

3.  Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.

Authors:  Iñigo Landa; Tihana Ibrahimpasic; Laura Boucai; Rileen Sinha; Jeffrey A Knauf; Ronak H Shah; Snjezana Dogan; Julio C Ricarte-Filho; Gnana P Krishnamoorthy; Bin Xu; Nikolaus Schultz; Michael F Berger; Chris Sander; Barry S Taylor; Ronald Ghossein; Ian Ganly; James A Fagin
Journal:  J Clin Invest       Date:  2016-02-15       Impact factor: 14.808

4.  High Diagnostic Accuracy Based on CLDN10, HMGA2, and LAMB3 Transcripts in Papillary Thyroid Carcinoma.

Authors:  Mateus Camargo Barros-Filho; Fabio Albuquerque Marchi; Clóvis Antônio Pinto; Silvia Regina Rogatto; Luiz Paulo Kowalski
Journal:  J Clin Endocrinol Metab       Date:  2015-04-13       Impact factor: 5.958

5.  Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.

Authors:  Karolina Holm; Dorthe Grabau; Kristina Lövgren; Steina Aradottir; Sofia Gruvberger-Saal; Jillian Howlin; Lao H Saal; Stephen P Ethier; Pär-Ola Bendahl; Olle Stål; Per Malmström; Mårten Fernö; Lisa Rydén; Cecilia Hegardt; Åke Borg; Markus Ringnér
Journal:  Mol Oncol       Date:  2012-06-20       Impact factor: 6.603

6.  Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.

Authors:  S Michael Rothenberg; David G McFadden; Edwin L Palmer; Gilbert H Daniels; Lori J Wirth
Journal:  Clin Cancer Res       Date:  2014-12-30       Impact factor: 12.531

7.  Epigenetic modifications in cutaneous malignant melanoma: EZH2, H3K4me2, and H3K27me3 immunohistochemical expression is enhanced at the invasion front of the tumor.

Authors:  Panagiotis Kampilafkos; Maria Melachrinou; Zinovia Kefalopoulou; John Lakoumentas; Georgia Sotiropoulou-Bonikou
Journal:  Am J Dermatopathol       Date:  2015-02       Impact factor: 1.533

8.  Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.

Authors:  Jie-Jen Lee; Tao-Yeuan Wang; Chien-Liang Liu; Ming-Nan Chien; Ming-Jen Chen; Yi-Chiung Hsu; Ching-Hsiang Leung; Shih-Ping Cheng
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

9.  Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation.

Authors:  Ming-Nan Chien; Po-Sheng Yang; Yi-Chiung Hsu; Tsang-Pai Liu; Jie-Jen Lee; Shih-Ping Cheng
Journal:  Head Neck       Date:  2018-08-13       Impact factor: 3.147

10.  Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics.

Authors:  Inga-Marie Schaefer; Christopher Dm Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2015-11-20       Impact factor: 7.842

View more
  4 in total

1.  Loss of Integrase Interactor 1 (INI1) Expression in a Subset of Differentiated Thyroid Cancer.

Authors:  Kung-Chen Ho; Jie-Jen Lee; Chi-Hsin Lin; Ching-Hsiang Leung; Shih-Ping Cheng
Journal:  Diagnostics (Basel)       Date:  2020-05-05

2.  Synergy of GSK-J4 With Doxorubicin in KRAS-Mutant Anaplastic Thyroid Cancer.

Authors:  Bo Lin; Bing Lu; I-Yun Hsieh; Zhen Liang; Zicheng Sun; Yang Yi; Weiming Lv; Wei Zhao; Jie Li
Journal:  Front Pharmacol       Date:  2020-05-13       Impact factor: 5.810

Review 3.  Polyphenols as Potent Epigenetics Agents for Cancer.

Authors:  Peramaiyan Rajendran; Salaheldin Abdelraouf Abdelsalam; Kaviyarasi Renu; Vishnupriya Veeraraghavan; Rebai Ben Ammar; Emad A Ahmed
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

4.  Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAFV600E by synergistically decreasing global trimethylation of H3K27.

Authors:  Hao Fu; Lin Cheng; Ri Sa; Yuchen Jin; Libo Chen
Journal:  J Cell Mol Med       Date:  2020-01-22       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.